BRAF and colorectal carcinoma: Phase I trials are being conducted in mCRC patients with BRAF mutations (BYL719 and LGX818 [BRAF inhibitor] with cetuximab) (NCT01719380) and CRC patients with PIK3CA mutations (MEN1611 and cetuximab) (NCT04495621) (135).